Latest stories on EIKN
Eikon Therapeutics Advances EIK1001 with First Patient Dosed in Landmark NSCLC Trial—What This Means for Cancer Treatment Innovation
July 27, 2026
MarketChameleon67 · bullishproduct/pr
Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer
Business Insider63 · neutralproduct/pr
Eikon Therapeutics: Behind The Rough Debut
Seeking Alpha38 · neutralgeneral
Is Eikon Therapeutics, Inc. (EIKN) Stock a Biotech Growth Opportunity Despite Limited Q1 Updates?
Yahoo Finance56 · neutralanalyst
Eikon Therapeutics to join Russell 3000 index
Seeking Alpha58 · neutralgeneral
Eikon Therapeutics to Join the Russell 3000® Index | EIKN Stock News
StockTitan63 · neutralgeneral
Eikon Therapeutics: Buy TLR Combinatory Potential Only After Lock-Up Expiry
Seeking Alpha38 · neutralanalyst
Eikon Therapeutics: Initiating Coverage With A Cautious Buy Rating
Seeking Alpha56 · neutralanalyst
Eikon Therapeutics Appoints Ma Fatima Francisco To Board
TipRanks55 · neutralgeneral
Eikon Therapeutics, Inc. (EIKN) files 8-K
SEC 8-K50 · neutralgeneral
Eikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors | EIKN Stock News
StockTitan55 · neutralgeneral
Eikon Highlights Promising New Clinical Data In Oncology
TipRanks63 · neutralproduct/pr